Cornea Day | ASCRS
thumbprint Session speaker
May 05, 2023
San Diego, CA

ASCRS Cornea Day

ASCRS Cornea Day highlights cataract and refractive surgery, corneal infections & keratoplasty procedures. 

Exceptional Educational Opportunities

The 2023 ASCRS Cornea Day will take place on May 5, 2022, in San Diego, CA, and features sections on challenging cornea cases, anterior and posterior lamellar surgery, controversies, and management of severe ocular surface diseases and takes an in-depth look at where the cornea field has been and where it’s going in the future.

Dr. Chang speaking

Program Chairs

Francis Mah, MD

Co-Chair

Marjan Farid, MD

Co-Chair

Thu
May 04, 2023

8:00 – 8:03 A.M.
Welcome

Marjan Farid, MD and Francis Mah, MD

8:03 – 9:35 A.M.
Session I: Updates in Surgical Cornea

Moderators: W. Barry Lee, MD and Winston Chamberlain, MD

Diagnosis and staging of Fuchs Dystrophy
8:02 – 8:07 A.M.
When to intervene —grading of Fuchs to help decide on surgery (specular/edema/Scheimpflug grading).
Sanjay Patel, MD
8:08 - 8:12 A.M.
Panel Discussion
Management of Endothelial disease
8:13 - 8:19 A.M.
DSO/DWEK – My current technique
Greg Moloney, MD
8:20 - 8:26 A.M.
DMEK –My current technique
Jennifer Rose-Nussbaumer, MD
8:27 - 8:33 A.M.
(Thin (ultra/nano) DSAEK is just as good as DMEK
Daniel Choi, MD
8:34 - 8:40 A.M.
DMEK in complex eyes
Sophie Deng, MD
8:41 - 8:47 A.M.
Overview of injectable endothelial cell therapy
Deepinder Dhaliwal, MD
8:48 - 8:54 A.M.
Update on Endothelial cell therapy clinical trials (The Aurion Biotech Discussion)
John Berdahl, MD
8:55 - 9:01 A.M.
Update on keratoprosthesis techniques
Tony Aldave, MD
9:02 - 9:08 A.M.
How Will eye Banking continue to stay relevant in the world of tissue culture/cell expansion/ bioengined corneas
Michelle Rhee, MD
9:09 - 9:15 A.M.
Panel Discussion
9:16 - 9:30 A.M.
Government Relations Update
Parag Parekh, MD
9:31 - 9: 34 A.M.
Session Concludes
9:50 - 12:00 P.M.
Session II: Office-Based Corneal Disease Management

Moderators: Sumit Garg, MD and Julie Schallhorn, MD

9:50 -9:54 A.M.
Intro to Session and Panelists
SA.M. Garg, Julie Schallhorn, Keith Walter, MD, Dave Hardten, MD
9:55 - 10:15 A.M.
Case 1: RES
Tanya Trinh, MD
10:15 - 10:35 A.M.
Case 2: CTL related keratitis
Neda Nikpoor, MD
10:35 - 10:55 A.M.
Case 3: Keratoconus
Nandini Venkateswaran, MD
11:00 - 11:20 A.M.
Case 4: Acanthamoeba
Olivia Lee, MD
11:20 - 11:40 A.M.
Case 5: Lumps and Bumps
Mitch Weikert, MD
11:40 A.M. - 12:00 P.M.
Case 6: Herpes
Gerami Seitzman, MD
1:00 – 2:00 P.M.
Session III: Complex Surgical Cornea Cases

Moderators: Brandon Ayres, MD, Leela Raju, MD and Naveen Rao, MD

1:00 - 1:01 P.M.
Welcome back
1:02 - 1:07 P.M.
Open sky secondary IOLs (Includes ARS Question)
Beeran Meghpara, MD
1:08 - 1:10 P.M.
Panel Discussion
1:20 - 1:25 P.M.
Complex DSEK/DMEK (under PK, in eye with tube shunt, vitrectomized eye, rebubble at slit lamp) (Includes ARS Question)
Chris Sales, MD
1:26 - 1:28 P.M.
Panel Discussion
1:29 - 1:34 P.M.
CE/IOL under PKP (Includes ARS Question)
Jonathan Rubenstein, MD
1:35 - 1:37 P.M.
Panel Discussion
1:38 - 1:43 P.M.
Iris Repair and artificial iris (Includes ARS Question)
Mike Snyder, MD
1:44 - 1:46 P.M.
Panel Discussion
1:47 - 1:52 P.M.
Peripheral thinning (Includes ARS Question)
Dean Ouano, MD
1:53 - 1:55 P.M.
Panel Discussion
1:56 - 2:00 P.M.
Final Panel Discussion and Session Conclude
2:15 – 3:45 p.m.
Session IV: The Ocular Surface

Moderators: Karolinne Rocha, MD and Zachary Zavodni, MD

Management of Surface Neoplasias
2:15 - 2:16 P.M.
Welcome Back
2:17 - 2:24 P.M.
OSSN
Carol Karp, MD
2:25 - 2:32 P.M.
What's that lesion and what do I do?
Soroosh Behshad, MD
2:33 - 2:39 P.M.
Panel Discussion
Severe Ocular Surface Disease Management
2:40 - 2:47 P.M.
Why is LSCD so underdiagnosed?
2:48 - 2:55 P.M.
Ocular Surface Reconstruction
2:56 - 3:03 P.M.
Management of acute Steven's Johnson
Chris Starr, MD
3:04 - 3:10 P.M.
Panel Discussion
Dry eye Disease Corner
3:11 - 3:18 P.M.
Updates in diagnostics
Preeya Gupta, MD
3:19 - 3:26 P.M.
Updates in treatments
Liz Yeu, MD
3:27 - 3:24 P.M.
Lid margin disease management
3:35 - 3:42 P.M.
Panel Discussion
3:43 - 3:45 P.M.
Session Wrap up

CME

Accreditation Statement

The American Society of Cataract and Refractive Surgery is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. ASCRS takes responsibility for the content, quality and scientific integrity of the CME activity.

Designation Statement

The American Society of Cataract and Refractive Surgery designates this live activity for a maximum of 6.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All CME activities approved for AMA PRA Category 1 CreditsTM are valid for recognition by the European Accreditation Council for Continuing Medical Education (EACCME). Physicians not licensed in the U.S. who participate in this CME activity are eligible for AMA PRA Category 1 CreditsTM.

Target Audience

Practicing ophthalmologists who care for patients with corneal-related conditions.

Educational Objectives

  • Describe updates in surgical cornea—management of Fuchs dystrophy, posterior lamellar keratoplasty updates, keratoprosthesis, and what is coming
  • Discuss office-based corneal disease management, including the management of keratoconus, corneal collagen crosslinking, herpes eye disease, and infectious keratitis
  • Examine current research related to the etiology and treatment of ocular surface diseases
  • Recognize current issues affecting global eye health and eye banking
  • Summarize strategies to identify and efficiently manage patients with ocular surface disease, dry eye disease and surface neoplasias


Claim CME/CE Credits

Attendees can evaluate the 2023 ASCRS Cornea Day Program online through the Claim CME/CE Credit Stations. When the evaluation is complete, a copy of the certificate for continuing education credits/hours for that day can be printed. If attendees do not complete the evaluation during the meeting, they will have the opportunity to complete them at home.

Notice About Off-Label Use Presentations

The ASCRS Annual Meeting may include presentations on drugs or devices or uses of drugs or devices that may not have been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice.

ASCRS is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations of off-label uses, does not imply an endorsement by ASCRS of the uses, products or techniques presented.